Previous 10 | Next 10 |
MindMed Reports Full Year 2021 Financial Results and Business Highlights Canada NewsWire - FDA cleared MindMed's Investigational New Drug (IND) application for Phase 2b dose optimization trial of MM-120 - - Progressed development programs for all three lead...
MindMed (NASDAQ:MNMD) said CFO David Guebert will retire on Mar. 31. MNMD retained an executive search firm to assist the board in identifying a new CFO with expertise and experience in the U.S. biotech market. For further details see: MindMed CFO David Guebert to retire
MindMed Announces Transition of CFO Canada NewsWire NEW YORK , March 25, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat...
ADN, BITF, CASI, ITRM, JEF, MNMD, SAIC, VERO, XPEV For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
The world may be a step closer to successfully treating obesity with psilocybin. That's because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you f...
MindMed to Host Earnings Call to Discuss Full-Year 2021 Financial Results and Provide Business Update Canada NewsWire NEW YORK , March 21, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical stage biopharmaceutical company d...
NeonMind Biosciences ( CSE:NEON)(OTC:NMDBF) is a step closer to bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders. With obesity, for example, worldwide obesity has tripled since 1975, says the World Health Organization. Plus,...
MindMed to Participate in March Investor Conferences PR Newswire NEW YORK , March 9, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing novel products to treat brain health disorder...
NetworkNewsWire Editorial Coverage New York, NY – March 2, 2022 – Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can’t be overstated. Indeed, the inability of the nervous system to change its activity in response...
MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects - Investigator-initiated double-blind placebo-controlled study conducted at the University Hospital Basel - PR Newswire NEW YORK , ...
News, Short Squeeze, Breakout and More Instantly...
Mind Medicine (MindMed) Inc. Company Name:
MNMD Stock Symbol:
NASDAQ Market:
Mind Medicine (MindMed) Inc. Website:
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie Fagan, effective today, as Chief Corpo...
2024-07-26 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed...